Aclarion, Inc. (ACONW) Stock Price & Analysis
Aclarion, Inc. (ACONW) rose 0.00% to USD 0.03 as of June 10, 2026 at 07:43 UTC, according to Nexqual real-time market data.
ACONW last closed at USD 0.03; the session ranged USD 0.03–0.03 on volume of 4,520 shares. Market capitalization is —, with a 52-week range of USD 0.03–0.03 (NCM). Source: Nexqual, June 10, 2026 at 07:43 UTC.
Key Statistics (as of June 10, 2026 at 07:43 UTC)
| Price | USD 0.03 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.03 |
| Open | USD 0.05 |
| Day Range | USD 0.03 – 0.03 |
| 52-Week Range | USD 0.03 – 0.03 |
| Volume | 4,520 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ACONW)
Nexqual's technical model rates ACONW "STRONG SELL" based on 0 bullish and 6 bearish signals across 66 daily candles, as of June 10, 2026 at 07:43 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.03) |
| MACD | 0 (negative) |
Analyst Ratings (ACONW)
Wall Street analysts rate ACONW "None", per Nexqual as of June 10, 2026 at 07:43 UTC.
| Consensus Rating | None |
|---|
Earnings (ACONW)
| Revenue Estimate | $30,000 |
|---|
Source: Nexqual, June 10, 2026 at 07:43 UTC.
Financials & Fundamentals (ACONW)
| Total Revenue | $77,879 |
|---|---|
| Revenue Growth (YoY) | +11.30% |
| Gross Margin | +19.34% |
| Operating Margin | -14129.33% |
| Profit Margin | +0.00% |
| ROE | -45.43% |
| Current Ratio | 19.65 |
| Total Cash | $19.00M |
| Total Debt | $0 |
| Free Cash Flow | $-4.86M |
Source: Nexqual, June 10, 2026 at 07:43 UTC.
Financial Health Score (ACONW)
Nexqual rates Aclarion, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:43 UTC.
| Growth | Strong — Revenue +66% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $19M cash, no debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -45%, ROA -28.8% |
Ownership (ACONW)
| Float | 2.21M |
|---|
Source: Nexqual, June 10, 2026 at 07:43 UTC.
Major Backers & Investors (ACONW)
Notable institutional backers of Aclarion, Inc. include CAPTRUST Financial Advisors, Palisades Hudson Asset Management, L.P., Clear Street Group Inc., according to Nexqual as of June 10, 2026 at 07:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| CAPTRUST Financial Advisors | 3.92% |
| Palisades Hudson Asset Management, L.P. | 2.8% |
| Clear Street Group Inc. | 2.35% |
Source: Nexqual, June 10, 2026 at 07:43 UTC.
From Aclarion, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Aclarion, Inc. operates as a healthcare technology company in the United States.
- It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments.
- The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.
- It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AIMDW | AINOS INC C/WTS 29/07/2027 (TO | USD 0.13 | ▲ 28.71% |
| ACON | Aclarion, Inc. | USD 3.26 | ▼ 8.68% |
| ADSEW | ADS-TEC ENERGY PLC Warrant | USD 0.49 | ▼ 37.31% |
| ADNWW | Advent Technologies Holdings, I | USD 0 | ▲ 2,800% |
| ALVOW | Alvotech Warrant | USD 0.3 | ▼ 10.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:43 UTC. This page is informational and not investment advice.